Skip to main content
GutCited
Figure 8

Descripción

Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms.

More Figures from This Paper

Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms.

Figure 6

Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms.

chart
Probiotic intervention outcomes assessed by IBS Severity Scoring System (IBS-SSS) in a three-arm clinical trial. Both Bifidobacterium lactis BI040 and Bacillus coagulans BC300 groups showed statistically significant improvement in total IBS-SSS scores compared to placebo.

Figure 7

Probiotic intervention outcomes assessed by IBS Severity Scoring System (IBS-SSS) in a three-arm clinical trial. Both Bifidobacterium lactis BI040 and Bacillus coagulans BC300 groups showed statistically significant improvement in total IBS-SSS scores compared to placebo.

chart
Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms.

Figure 9

Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms.

chart

Figure 8

Chart
1435 × 746px · 414,7 KB

Source Paper

The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in Adult Patients with Irritable Bowel …

Journal of clinical medicine (2023)

PMID: 37510953

DOI: 10.3390/jcm12144838

Cite This Figure

![Figure 8: Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms.](https://pdfs.citedhealth.com/figures/37510953/261.png)

> Source: Barbara Skrzydło-Radomańska et al. "The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifid." *Journal of clinical medicine*, 2023. PMID: [37510953](https://pubmed.ncbi.nlm.nih.gov/37510953/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/37510953/261.png" alt="Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms." />
  <figcaption>Figure 8. Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms.<br>  Source: Barbara Skrzydło-Radomańska et al. "The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifid." <em>Journal of clinical medicine</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37510953/">37510953</a></figcaption>
</figure>

Evidencia relacionada

B
Bacillus coagulans para Irritable Bowel Syndrome (IBS)

Calificación B · 3 estudios

 B
Bifidobacterium lactis para Chronic Constipation

Calificación B · 4 estudios